Joint modelling of progression-free and overall survival and computation of correlation measures

In this paper, we derive the joint distribution of progression-free and overall survival as a function of transition probabilities in a multistate model. No assumptions on copulae or latent event times are needed and the model is allowed to be non-Markov. From the joint distribution, statistics of interest can then be computed. As an example, we provide closed formulas and statistical inference for Pearson's correlation coefficient between progression-free and overall survival in a parametric framework. The example is inspired by recent approaches to quantify the dependence between progression-free survival, a common primary outcome in Phase 3 trials in oncology and overall survival. We complement these approaches by providing methods of statistical inference while at the same time working within a much more parsimonious modeling framework. Our approach is completely general and can be applied to other measures of dependence. We also discuss extensions to nonparametric inference. Our analytical results are illustrated using a large randomized clinical trial in breast cancer.

[1]  Hui Xie,et al.  The Price of Kaplan–Meier , 2004 .

[2]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[3]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[4]  M Buyse,et al.  On the relationship between response to treatment and survival time. , 1996, Statistics in medicine.

[5]  Bradley Efron,et al.  Censored Data and the Bootstrap , 1981 .

[6]  Richard Pazdur,et al.  Endpoints for assessing drug activity in clinical trials. , 2008, The oncologist.

[7]  Yimei Li,et al.  A Weibull multi‐state model for the dependence of progression‐free survival and overall survival , 2015, Statistics in medicine.

[8]  Michael LeBlanc,et al.  Interim futility analysis with intermediate endpoints , 2008, Clinical trials.

[9]  Zheng Su,et al.  A hybrid approach to predicting events in clinical trials with time-to-event outcomes. , 2011, Contemporary clinical trials.

[10]  O. Aalen,et al.  Survival and Event History Analysis: A Process Point of View , 2008 .

[11]  Odd O. Aalen,et al.  Dynamic modelling and causality , 1987 .

[12]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .

[13]  Christopher H Jackson,et al.  flexsurv: A Platform for Parametric Survival Modeling in R. , 2016, Journal of statistical software.

[14]  O. Aalen.  Nonparametric Inference for a Family of Counting Processes , 1978 .

[15]  Andrew C Titman,et al.  Quantifying the association between progression‐free survival and overall survival in oncology trials using Kendall's τ , 2018, Statistics in medicine.

[16]  M Buyse,et al.  Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  P. Andersen,et al.  Decomposition of number of life years lost according to causes of death , 2013, Statistics in medicine.

[18]  Hein Putter,et al.  Non-parametric estimation of transition probabilities in non-Markov multi-state models: The landmark Aalen–Johansen estimator , 2018, Statistical methods in medical research.

[19]  Martin Schumacher,et al.  A wild bootstrap approach for the Aalen–Johansen estimator , 2018, Biometrics.

[20]  D. Sargent,et al.  Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H Putter,et al.  Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.

[22]  T. Choueiri,et al.  Progression‐free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy , 2011, Cancer.

[23]  C. Weir,et al.  Statistical evaluation of biomarkers as surrogate endpoints: a literature review , 2006, Statistics in medicine.

[24]  Philip Hougaard,et al.  Analysis of Multivariate Survival Data , 2001 .

[25]  Michael J Crowther,et al.  Simulating biologically plausible complex survival data , 2013, Statistics in medicine.

[26]  Somnath Datta,et al.  Validity of the Aalen–Johansen estimators of stage occupation probabilities and Nelson–Aalen estimators of integrated transition hazards for non-Markov models , 2001 .

[27]  Per Kragh Andersen,et al.  Life years lost among patients with a given disease , 2017, Statistics in medicine.

[28]  Virginie Rondeau,et al.  A joint frailty-copula model between tumour progression and death for meta-analysis , 2017, Statistical methods in medical research.

[29]  Martin Schumacher,et al.  Basic parametric analysis for a multi-state model in hospital epidemiology , 2017, BMC Medical Research Methodology.

[30]  V. Prasad,et al.  The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. , 2015, JAMA internal medicine.

[31]  J. Thigpen,et al.  Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .

[32]  Haoda Fu,et al.  Joint modeling of progression‐free survival and overall survival by a Bayesian normal induced copula estimation model , 2013, Statistics in medicine.

[33]  Richard J Cook,et al.  Design of cancer trials based on progression‐free survival with intermittent assessment , 2018, Statistics in medicine.

[34]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[35]  Juanjuan Fan,et al.  A class of weighted dependence measures for bivariate failure time data , 2000 .

[36]  Martin Schumacher,et al.  Competing Risks and Multistate Models with R , 2011 .

[37]  Andrea Manca,et al.  Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[38]  Ren Johansen.  An Empirical Transition Matrix for Non-homogeneous Markov Chains Based on Censored Observations , 1978 .

[39]  Martin Schumacher,et al.  Simulating competing risks data in survival analysis , 2009, Statistics in medicine.

[40]  Maja Pohar Perme,et al.  Inference for outcome probabilities in multi-state models , 2008, Lifetime data analysis.

[41]  E. Bluhmki,et al.  A statistical model for the dependence between progression‐free survival and overall survival , 2009, Statistics in medicine.

[42]  Niels Keiding,et al.  Statistical Models Based on Counting Processes , 1993 .

[43]  C. L. Chiang,et al.  Competing risks in mortality analysis. , 1991, Annual review of public health.

[44]  Carmen Cadarso-Suárez,et al.  Nonparametric estimation of transition probabilities in a non-Markov illness–death model , 2006, Lifetime data analysis.

[45]  Chikuma Hamada,et al.  Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework , 2018, Journal of biopharmaceutical statistics.

[46]  Geert Molenberghs,et al.  Statistical evaluation of surrogate endpoints with examples from cancer clinical trials , 2016, Biometrical journal. Biometrische Zeitschrift.

[47]  N. Keiding,et al.  Multi-state models for event history analysis , 2002, Statistical methods in medical research.

[48]  Stephen L. George,et al.  A Multi-State Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression , 2016, Statistics in biopharmaceutical research.